LDFWART With Docetaxel in Patients With Platinum-Resistant Recurrent Ovarian Carcinoma

Inclusion Criteria: * 1\. Patients must have platinum-resistant disease relapsing within 6 months or less from the date of their last cycle of initial adjuvant chemotherapy recurrent adenocarcinoma from a primary ovarian, tubal, or peritoneal cancer following first-line chemotherapy for metastatic disease. There is no limit on prior number of chemotherapy regimens. Patients who have received prior systemic docetaxel and platinum-based chemotherapy are eligible * 1.1 Patients must have ≥ 1cm measurable disease on imaging studies independent of patients having an optional surgical salvage procedure. * 2\. Patients must have a life expectancy of at least 6 months. * 3\. Patients must have Karnofsky performance status of ≥ 60 or Gynecology Oncology (GOG) performance status of ≤ 2 (see www.GOG.org website). * 4\. Age 18 - 80 years old * 5\. Patients must have an adequate bone marrow, renal, and hepatic function: * 5.1 WBC: ≥ 3,000 /mcl * 5.2 ANC: ≥ 1,500 /mcl * 5.3 Platelets: ≥ 100,000 /mcl * 5.4 Creatinine: \< 2.0 mg/dcl * 5.5 Bilirubin: \< 1.5x institutional normal value * 5.6 LDH, GGT, SGPT (ALT), SGOT (AST), and ALK Phos:\< 3x institutional normal value. * 6\. Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * 1\. Patients who have received prior radiotherapy to the chest, whole abdomen, or lower extremities above the knees. * 2\. Patients who have received prior radiation therapy to the head, neck, or lower extremities below the knees if greater than 3 years prior to study entry. * 3\. Evidence of extra-abdominal extension of disease (such as groin nodes, lung, supraclavicular nodes, and pleural fluid). * 4\. Patients may not be receiving any other investigational agents within 4 weeks preceding the start of study treatment) or chemotherapy for at least 3 weeks preceding the start of study treatment. * 5\. Patients who have been diagnosed with another prior malignant tumor within 3 years of study entry, excluding non-melanoma skin cancer and carcinoma in situ of the cervix. * 6\. Patients with prior history of a severe hypersensitivity reaction to paclitaxel (polysorbate 80-Cremophor). * 7\. Patients with current history of uncontrolled hypertension, angina pectoris, heart failure, cardiac dysrhythmias, pericardial disease, cardiomyopathy, or active infection. * 8\. Presence of any medical condition that in the opinion of the investigator deems the patient unable to participate. * 9\. Females of child-bearing potential. It is expected that ovarian cancer patients would have had a hysterectomy and/or oophorectomy as part of the original standard of care. * 10\. Patients that are \< 18 yrs. of age or \> 80 yrs. of age.